Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.076
Sell
RSI(14)
39.873
Neutral
STOCH(KDJ)(9,3,3)
29.430
Neutral
ATR(14)
0.259
Low Volatility
CCI(14)
-145.933
Sell
Williams %R
91.892
Oversold
TRIX(12,20)
-0.325
Sell
StochRSI(14)
0.000
Sell
Prime Medicine Inc
PRME3.380USD
-0.260-7.14%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
323.57MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Prime Medicine Inc
Currency: USD Updated: 2026-03-27Key Insights
Prime Medicine Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 158 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.92.In the medium term, the stock price is expected to remain stable.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prime Medicine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
Prime Medicine Inc Highlights
StrengthsRisks
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.63M.
Fairly Valued
The company’s latest PE is -2.50, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 113.38M shares, increasing 19.19% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.15M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 1.24.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
6.917
Target Price
+90.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Prime Medicine Inc is 5.47, ranking 359 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 838.00K, representing a year-over-year decrease of 61.61%, while its net profit experienced a year-over-year decrease of 9.00%.
Score
Financials
5.26
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.52
Operational Efficiency
2.72
Growth Potential
4.76
Shareholder Returns
7.11
Prime Medicine Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Prime Medicine Inc is 5.76, ranking 362 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.50, which is -71.42% below the recent high of -0.71 and -478.07% above the recent low of -14.45.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 158/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Prime Medicine Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 9.00 and a low of 4.25.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
6.917
Target Price
+90.02%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Prime Medicine Inc
PRME
13
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Prime Medicine Inc is 5.86, ranking 296 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.33 and the support level at 2.86, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.550
Sell
MA10
3.586
Sell
MA20
3.809
Sell
MA50
3.802
Sell
MA100
3.807
Sell
MA200
3.981
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Prime Medicine Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.81%, representing a quarter-over-quarter increase of 32.47%. The largest institutional shareholder is The Vanguard, holding a total of 6.44M shares, representing 3.57% of shares outstanding, with 28.64% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Liu (David R)
ARCH Venture Partners
Alphabet, Inc.
BlackRock Institutional Trust Company, N.A.
Newpath Partners LP
T. Rowe Price Investment Management, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Prime Medicine Inc is 3.35, ranking 143 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.65. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.63
VaR
--
240-Day Maximum Drawdown
+51.42%
240-Day Volatility
+110.02%
Return
Best Daily Return
60 days
+16.58%
120 days
+16.58%
5 years
--
Worst Daily Return
60 days
-9.23%
120 days
-9.55%
5 years
--
Sharpe Ratio
60 days
+0.41
120 days
-1.09
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+51.42%
3 years
+93.26%
5 years
--
Return-to-Drawdown Ratio
240 days
+3.00
3 years
-0.26
5 years
--
Skewness
240 days
+0.83
3 years
+0.68
5 years
--
Volatility
Realised Volatility
240 days
+110.02%
5 years
--
Standardised True Range
240 days
+10.21%
5 years
--
Downside Risk-Adjusted Return
120 days
-228.60%
240 days
-228.60%
Maximum Daily Upside Volatility
60 days
+64.83%
Maximum Daily Downside Volatility
60 days
+49.33%
Liquidity
Average Turnover Rate
60 days
+3.29%
120 days
+2.36%
5 years
--
Turnover Deviation
20 days
+124.02%
60 days
+174.77%
120 days
+97.51%
Peer Comparison
Biotechnology & Medical Research
Prime Medicine Inc
PRME
5.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
